title: HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.
abstract: BACKGROUND
  In the continuing effort to introduce antiretroviral therapy in resource-limited settings, there is a need to understand differences between natural history of HIV in different populations and to identify feasible clinical measures predictive of survival.
  
  
  METHODS
  We examined predictors of survival among 836 heterosexuals who were infected with HIV subtype CRF01_AE in Thailand.
  
  
  RESULTS
  From 1993 to 1999, 269 (49.4%) men and 65 (25.7%) women died. The median time from the estimated seroconversion to death was 7.8 years (95% confidence interval 7.0-9.1). Men and women with enrolment CD4 counts <200 cells/microl had about 2 and 11 times greater risk of death than those with CD4 counts of 200-500 and >500, respectively. Measurements available in resource-limited settings, including total lymphocyte count (TLC), anaemia, and low body mass index (BMI), also predicted survival. Men with two or more of these predictors had a median survival of 0.8 (0.5-1.8) years, compared with 2.7 (1.9-3.3) years for one predictor and 4.9 (4.1-5.2) years for no predictors.
  
  
  CONCLUSIONS
  The time from HIV infection to death appears shorter among this Thai population than among antiretroviral naive Western populations. CD4 count and viral load (VL) were strong, independent predictors of survival. When CD4 count and VL are unavailable, individuals at high risk for shortened HIV survival may be identified by a combination of low TLC, anaemia, and low BMI. This combination of accessible clinical measures of the disease stage may be useful for medical management in resource-limited settings.
authors.affiliation: Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Costello
authors.forename: K E
authors.initials: KE
authors.lastname: Nelson
authors.forename: V
authors.initials: V
authors.lastname: Suriyanon
authors.forename: S
authors.initials: S
authors.lastname: Sennun
authors.forename: S
authors.initials: S
authors.lastname: Tovanabutra
authors.forename: C M
authors.initials: CM
authors.lastname: Heilig
authors.forename: S
authors.initials: S
authors.lastname: Shiboski
authors.forename: D J
authors.initials: DJ
authors.lastname: Jamieson
authors.forename: V
authors.initials: V
authors.lastname: Robison
authors.forename: K
authors.initials: K
authors.lastname: Rungruenthanakit
authors.forename: A
authors.initials: A
authors.lastname: Duerr
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000740:Anemia / Q000150:complications / Q000453:epidemiology; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D015992:Body Mass Index; D018791:CD4 Lymphocyte Count / Q000379:methods; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality*; D015497:HIV-1; D020010:Heterosexuality; D006801:Humans; D018655:Lymphocyte Count / Q000379:methods; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D017678:Sex Distribution; D013785:Thailand / Q000453:epidemiology
chemical_list: D044966:Anti-Retroviral Agents